#USA #Ann Arbor #Akadeum Life Sciences #CDMO Alliance #Microbubble Technology

Akadeum Life Sciences Launches CDMO Alliance Program

Akadeum Life Sciences, a pioneering force in the field of buoyant cell separation, recently announced its new Akadeum CDMO Alliance. This innovative initiative is set to revolutionize the landscape of cell therapy manufacturing, with the primary goal of enhancing efficiency, reducing costs, and broadening access to cutting-edge cell therapies. The alliance officially welcomed its first two members: Charles River and ElevateBio, both recognized leaders in cell therapy production.

The Need for Innovation in Cell Therapies

As demand for effective cell therapies continues to grow, manufacturers face increasing pressure to streamline their processes and improve cost-effectiveness without compromising quality. Traditional methods of cell separation can be labor-intensive and costly, often leading to reduced efficiency and longer production times. Akadeum aims to address these challenges by harnessing the power of its proprietary microbubble technology to enhance cell separation procedures.

The Akadeum CDMO Alliance Explained

The Akadeum CDMO Alliance™ seeks to establish a consortium of leading contract development and manufacturing organizations (CDMOs) to foster innovation in the field of cell therapies. This alliance will serve as a collaborative platform that empowers its members to access orchestrated insights and the latest technologies in the industry. The alliance is designed to remain exclusive, limiting its membership to just five CDMOs to ensure high engagement and personalized support.

The inaugural members, Charles River and ElevateBio, will be granted early access to Akadeum’s advanced kits and technologies in development. This privileged position allows them to be at the cutting edge of innovation, leveraging the benefits of microbubble technology that drives cost savings of up to 40% in cell therapy manufacturing workflows.

Member Benefits

Participants in the Akadeum CDMO Alliance gain several competitive advantages:

• - Early Access to Innovations: Members will receive insights into Akadeum’s technology pipeline and will be among the first to pilot new products and solutions developed within the alliance.
• - Customized Support: Each member will benefit from tailored technical and regulatory support, ensuring they can maximize the advantages of Akadeum’s technologies in their product development.
• - Enhanced Collaboration: The alliance promotes direct engagement with Akadeum's R&D team, facilitating collaboration that can drive innovation.

Microbubble Technology: The Game Changer

Microbubbles represent a significant advancement in cell separation methods. They effectively utilize buoyancy to float unwanted cells to the surface, enabling a truly negative selection approach that retains the integrity of the desired cells.

Some notable benefits of this technology include:

• - Increased Cell Viability: Reduced handling and minimized contamination during separation processes significantly increase the viability of T cells.
• - Efficiency: The entire cell separation can be completed in under an hour, allowing for faster production cycles and enabling manufacturers to initiate more workflows on fewer production lines.
• - Lower Operational Costs: By using existing equipment and space, CDMOs can achieve substantial operational savings, making cell therapies more accessible to a larger patient population.

Goals for the Future

As the Akadeum CDMO Alliance unfolds, the expectation is to define new benchmarks in therapeutic manufacturing that not only enhance quality but also accelerate timelines to market. The alliance embodies a strategic move towards creating a more streamlined, efficient, and cost-effective pathway from development to commercialization in the realm of cell therapies.

Brandon McNaughton, CEO of Akadeum, stated, “The launch of the Akadeum CDMO Alliance is an essential step towards uniting technologies and capabilities that will drive forward the future of cell therapy. We’re eager to collaborate with innovative CDMOs that are committed to increasing access and reducing the time between patient and therapy.”

About Akadeum Life Sciences

Founded with the mission to advance human health through innovative separation technologies, Akadeum Life Sciences specializes in buoyant microbubble technology that enhances efficiency in cell separation. Their goal is to empower research and clinical applications with tools that unlock breakthroughs in various healthcare fields. To learn more, visit www.akadeum.com.